(Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 ...

The most significant addition was Regeneron Pharmaceuticals Inc (NASDAQ:REGN), with 114,880 shares, accounting for 3.88% of ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has ...

Shares of Regeneron Pharmaceuticals Inc. REGN advanced 2.39% to $584.99 Thursday, on what proved to be an all-around positive ...

Regeneron's lead counsel was Jonathan D. Polkes of White & Case LLP.

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws, and gave ...

During a live event, Xiuning Le, MD, PhD, discussed clinical trials of supportive care for infusion reaction and skin rash ...

Asthma biologics can be continued and initiated during conception, throughout pregnancy and while breastfeeding, especially ...

The US Court of Appeals for the First Circuit’s landmark decision in United States v. Regeneron Pharmaceuticals will have some implications ...

As of mid-May 2025, the S&P 500 has turned positive year-to-date (YTD) for the first time in many weeks. Stocks across ...

Explore Regeneron Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for REGN. Sanofi plans $20 billion US investment by 2030 to expand R&D and ...